The relationship between self-reported substance use and psychiatric symptoms in low-threshold methadone maintenance treatment clients

Table 4 Multiple regressions of past 30 day substance-use predicting psychiatric symptoms

Dependent Variable (# of symptoms endorsed on PDSQ)	Model F(6,67) =	p	Adjusted R²	Significant predictors (p)	Beta
Psychosis	1.44	.212	.04
Hypochondriasis	1.71	.133	.06
Somatization disorder	1.83	.107	.06
Depression	6.16	<.001	.27	-Any non-prescribed benzodiazepine use (<.001)	.58
PTSD	3.60	.004	.18	-Any non-prescribed benzodiazepine use (<.001)	.46
OCD	3.99	.002	.20	-Any non-prescribed benzodiazepine use (<.001)	.44
Panic disorder	2.42	.035	.11	-Any non-prescribed benzodiazepine use (.001)	.41
Agoraphobia	1.40	.226	.03
Social phobia	2.73	.020	.12	-Any non-prescribed benzodiazepine use (.004)	.37
GAD	6.06	<.001	.29	-Any non-prescribed benzodiazepine use (<.001)	.60
Total number of all symptoms assessed	3.08	.010	.15	-Any non-prescribed benzodiazepine use (<.001)	.49

*Predictors entered in all regressions: Any non-prescribed benzodiazepine use, Only prescribed benzodiazepine use, Any non-prescribed prescription opioid use, Any alcohol use, Any cannabis use, and Any crack use in the past 30 days.
**Significant univariate predictors are presented only in the case of a significant multivariate model.

ISSN: 1477-7517